Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat.
Jessica E. Malberg, K E Sabol, Lewis S. Seiden
Journal of Pharmacology and Experimental Therapeutics July 1, 1996 DOI: 10.1016/s0022-3565(25)20131-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study Peer reviewed |
|---|---|
| Population | Male Holtzmann rats |
| Interventions | MDMA ketanserin alpha-methyl-p-tyrosine fluoxetine saline |
| Dose | MDMA 40 mg/kg; ketanserin 6 mg/kg; alpha-methyl-p-tyrosine 75 mg/kg; fluoxetine 10 mg/kg |
| Duration | Core temperature recorded for up to 240 minutes after MDMA; brain regions analyzed two weeks later |
| Topics | MDMA |
| Keywords | Animals Rats N-methyl-3,4-methylenedioxyamphetamine Fluoxetine Ketanserin Tyrosine Drug combinations Body temperature Male |
| Key findings | Pretreatment with ketanserin or alpha-methyl-p-tyrosine produced prolonged hypothermia after MDMA and prevented MDMA-induced serotonin and 5-HIAA depletions in frontal cortex, somatosensory cortex, striatum, and hippocampus, but warming the rats abolished this protection, indicating the hypothermia mediated it. Fluoxetine pretreatment caused no temperature change yet still protected against the same depletions, suggesting a protection mechanism independent of body temperature. |
Abstract
The substituted amphetamine 3,4-methylenedioxymethamphetamine (MDMA) has been shown to be neurotoxic to serotonin (5HT) terminals in the rat, and rat body temperature (TEMP) has been shown to affect this neurotoxicity. This study looked at the effect on CORE TEMP of three drugs that protect against MDMA neurotoxicity in the rat. Male Holtzmann rats were injected with a control saline (SAL) injection or with ketanserin (KET; 6 mg/kg), alpha-methyl-p-tyrosine (AMPT; 75 mg/kg) or fluoxetine (FLUOX; 10 mg/kg) before a 40-mg/kg MDMA or SAL injection. CORE TEMP was recorded throughout the study using a noninvasive peritoneally implanted temperature probe. Rats pretreated with KET had no change in CORE TEMP until MDMA was injected, at which time an immediate hypothermia was seen that continued for 180 minutes, with a peak low of 34.7 degrees C. Rats treated with AMPT had no change in CORE TEMP until the MDMA was injected, at which time an immediate hypothermia was seen that continued for 240 min., with a peak low of 34.3 degrees C. Two weeks later, brain regions were analyzed for 5-HT and 5-hydroxindole acetic acid levels. MDMA produced significant (P < .05) decreases in 5-HT and 5-hydroxindole acetic acid levels in the frontal cortex, somatosensory cortex, striatum and hippocampus, and pretreatment with KET or AMPT prevented these depletions. When rats were given the KET/MDMA or AMPT/MDMA drug injections and warmed to prevent hypothermia, the protection against neurotoxicity was removed, which indicated that the hypothermia mediated the protective effects of KET and AMPT. In comparison with the hypothermia seen with AMPT or KET pretreatment, pretreatment with FLUOX had no effect on CORE TEMP. The rats given the FLUOX/MDMA treatment did not have different CORE TEMPs than rats given SAL/MDMA. The FLUOX pretreatment protected against MDMA-induced 5-HT and 5-hydroxindole acetic acid depletions in the frontal cortex, somatosensory cortex, striatum and hippocampus. This study suggests that a decrease in CORE TEMP may be a mechanism of protection against MDMA neurotoxicity by some drugs but that there is also a mechanism of protection that is independent of a change in body temperature.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 54
- Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat Journal of Neuroscience July 1, 1998
- The pharmacology of the acute hyperthermic response that follows administration of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats British Journal of Pharmacology 2002
- The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers Journal of Psychopharmacology May 1, 2000
- A study of the mechanisms involved in the neurotoxic action of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain British Journal of Pharmacology December 1, 2001
- The mechanisms involved in the long‐lasting neuroprotective effect of fluoxetine against MDMA (‘ecstasy’)‐induced degeneration of 5‐HT nerve endings in rat brain British Journal of Pharmacology September 1, 2001
and 49 more in the library